{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:54:05Z","timestamp":1763758445157,"version":"3.45.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.coph.2025.102582","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:47:53Z","timestamp":1760662073000},"page":"102582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CRISPR-Cas9 in acute myeloid leukaemia: Current state-of-art and future perspectives"],"prefix":"10.1016","volume":"85","author":[{"given":"Federico","family":"Zingarelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Curti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2025.102582_bib1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable Dual-RNA\u2013Guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.coph.2025.102582_bib2","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1016\/j.coph.2025.102582_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/srep23549","article-title":"Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing","volume":"6","author":"Miyaoka","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2025.102582_bib4","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1038\/s41467-023-41501-5","article-title":"Structural basis for the activation of a compact CRISPR-Cas13 nuclease","volume":"14","author":"Deng","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102582_bib5","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/cells9061337","article-title":"Transposon-Based CAR T cells in acute leukemias: where are we going?","volume":"9","author":"Magnani","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.coph.2025.102582_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102582_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102582_bib8","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102582_bib9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.leukres.2008.11.011","article-title":"In vitro biology of human myeloid leukemia","volume":"33","author":"Mayani","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.coph.2025.102582_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ygeno.2016.04.003","article-title":"Changes of heterogeneous cell populations in the Ishikawa cell line during long-term culture: proposal for an in vitro clonal evolution model of tumor cells","volume":"107","author":"Kasai","year":"2016","journal-title":"Genomics"},{"key":"10.1016\/j.coph.2025.102582_bib11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/10428199809059223","article-title":"History and classification of human leukemia-lymphoma cell lines","volume":"31","author":"Drexler","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.coph.2025.102582_bib12","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1074\/mcp.RA119.001504","article-title":"Phosphotyrosine-based phosphoproteomics for target identification and drug response prediction in AML cell lines","volume":"19","author":"van Alphen","year":"2020","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.coph.2025.102582_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3390\/cells11050854","article-title":"RNAi-Mediated screen of primary AML cells nominates MDM4 as a therapeutic target in NK-AML with DNMT3A mutations","volume":"11","author":"Sidorova","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.coph.2025.102582_bib14","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1158\/0008-5472.CAN-16-1627","article-title":"A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220","volume":"77","author":"Hou","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.coph.2025.102582_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.753276","article-title":"Rapid and sensitive diagnosis of drug-resistant FLT3-F691L mutation by CRISPR detection","volume":"8","author":"Liu","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.coph.2025.102582_bib16","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood.2023022908","article-title":"CRISPR-Based rapid molecular diagnostic tests for fusion-driven leukemias","volume":"144","author":"Vedula","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102582_bib17","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1158\/1078-0432.CCR-22-1618","article-title":"Large-scale in vitro and in vivo CRISPR-Cas9 knockout screens identify a 16-Gene fitness score for improved risk assessment in acute Myeloid leukemia","volume":"28","author":"Jin","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102582_bib18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.stem.2020.12.005","article-title":"Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.coph.2025.102582_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2020.257964","article-title":"A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia","volume":"107","author":"Damnernsawad","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2025.102582_bib20","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in Acute Myeloid Leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102582_bib21","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in Acute Myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102582_bib22","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/nprot.2017.088","article-title":"Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice","volume":"12","author":"Reinisch","year":"2017","journal-title":"Nat Protoc"},{"key":"10.1016\/j.coph.2025.102582_bib23","doi-asserted-by":"crossref","first-page":"12043","DOI":"10.1073\/pnas.0902449106","article-title":"A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO","volume":"106","author":"Osman","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coph.2025.102582_bib24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nm.4283","article-title":"The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia","volume":"23","author":"Fenouille","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102582_bib25","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102582_bib26","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1080\/10428194.2020.1805740","article-title":"Modeling pediatric AML FLT3 mutations using CRISPR\/Cas12a- mediated gene editing","volume":"61","author":"Rivera-Torres","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.coph.2025.102582_sref27","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-023-02041-5","article-title":"PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia","author":"Alshamleh","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102582_bib28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102582_sref29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","article-title":"Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1","volume":"13","author":"Fiskus","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coph.2025.102582_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-022-00654-0","article-title":"Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with \u201c7+3.\u201d","volume":"12","author":"Begna","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coph.2025.102582_sref31","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/s41375-023-01950-9","article-title":"Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo","volume":"37","author":"Neldeborg","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.coph.2025.102582_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.3471","article-title":"Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo","volume":"34","author":"Yin","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coph.2025.102582_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg3217","article-title":"Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy","volume":"7","author":"Ho","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.coph.2025.102582_bib34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.stem.2019.08.003","article-title":"Cohesin members Stag1 and Stag2 display distinct roles in chromatin accessibility and topological control of HSC self-renewal and differentiation","volume":"25","author":"Viny","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.coph.2025.102582_bib35","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41467-019-09469-3","article-title":"Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia","volume":"10","author":"Yang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102582_bib36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia","volume":"157","author":"Gr\u00f6schel","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.coph.2025.102582_bib37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-022-05365-x","article-title":"Subtype-specific 3D genome alteration in acute myeloid leukaemia","volume":"611","author":"Xu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102582_bib38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood.2023021234","article-title":"Transcriptional control of leukemogenesis by the chromatin reader SGF29","volume":"143","author":"Barbosa","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102582_bib39","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51754","article-title":"Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells","volume":"9","author":"Domingues","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.coph.2025.102582_bib40","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","article-title":"A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute Myeloid leukemia","volume":"17","author":"Tzelepis","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.coph.2025.102582_bib41","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13046-019-1397-3","article-title":"Iron and leukemia: new insights for future treatments","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.coph.2025.102582_bib42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3324\/haematol.2020.259531","article-title":"APR-246 induces early cell death by ferroptosis in acute myeloid leukemia","volume":"107","author":"Birsen","year":"2021","journal-title":"Haematol"},{"key":"10.1016\/j.coph.2025.102582_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.959738","article-title":"A ferroptosis-related gene signature and immune infiltration patterns predict the overall survival in acute myeloid leukemia patients","volume":"9","author":"Yin","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.coph.2025.102582_sref44","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-023-00653-5","article-title":"Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia","author":"Bruedigam","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.coph.2025.102582_bib45","first-page":"48","article-title":"Imetelstat achieves meaningful and durable transfusion Independence in high transfusion\u2013burden patients with lower-risk myelodysplastic syndromes in a phase II Study","volume":"39","author":"Steensma","year":"2021","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.coph.2025.102582_bib46","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1038\/s41467-018-07901-8","article-title":"Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities","volume":"9","author":"Sanson","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102582_bib47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/bloodadvances.2023010786","article-title":"The nonessential amino acid cysteine is required to prevent ferroptosis in acute myeloid leukemia","volume":"8","author":"Cunningham","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102582_bib48","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute Myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102582_bib49","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102582_bib50","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coph.2025.102582_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coph.2025.102582_sref52","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1038\/s41467-023-41229-2","article-title":"ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia","volume":"14","author":"Ebner","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102582_bib53","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/2159-8290.CD-20-1851","article-title":"An In Vivo CRISPR screening platform for prioritizing therapeutic targets in AML","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coph.2025.102582_sref54","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1182\/bloodadvances.2022009455","article-title":"In vivo CRISPR\/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice","volume":"7","author":"Li","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102582_sref55","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1182\/bloodadvances.2022007934","article-title":"Genome-wide CRISPR\/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML","volume":"7","author":"Nguyen","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102582_bib56","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41698-024-00643-5","article-title":"Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials","volume":"8","author":"Elsayed A","year":"2024","journal-title":"Npj Precis Onc"},{"key":"10.1016\/j.coph.2025.102582_bib57","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102582_bib58","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V130.Suppl_1.814.814","article-title":"TAK-243 is a selective UBA1 inhibitor that displays preclinical activity in Acute Myeloid Leukemia (AML)","volume":"130","author":"Barghout","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102582_bib59","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141518","article-title":"A genome-wide CRISPR\/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity","volume":"6","author":"Barghout","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.coph.2025.102582_bib60","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood.2019004108","article-title":"CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy","volume":"137","author":"Soares","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102582_bib61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/abt\/tbad025","article-title":"Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML","volume":"7","author":"Morse","year":"2024","journal-title":"Antibody Therapeutics"},{"volume":"123","year":"2014","author":"Vaughan","key":"10.1016\/j.coph.2025.102582_bib62"},{"key":"10.1016\/j.coph.2025.102582_bib63","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1182\/bloodadvances.2021004770","article-title":"Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment","volume":"5","author":"Nowicka","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102582_bib64","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/bloodadvances.2022008926","article-title":"Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation","volume":"8","author":"Fuchs","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102582_bib65","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ccell.2018.01.012","article-title":"Genome-wide CRISPR-Cas9 screen identifies leukemia-specific dependence on a Pre-mRNA metabolic pathway regulated by DCPS","volume":"33","author":"Yamauchi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102582_bib66","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102582_bib67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40364-022-00390-4","article-title":"Integrated multiomic approach for identification of novel immunotherapeutic targets in AML","volume":"10","author":"K\u00f6hnke","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.coph.2025.102582_bib68","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"Gottschlich","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coph.2025.102582_bib69","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102582_bib70","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.coph.2025.102582_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1459818","article-title":"A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?","volume":"15","author":"Andrea","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2025.102582_bib72","article-title":"Simultaneous editing of TCR, HLA-I\/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2025.102582_bib73","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102582_bib74","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102582_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102582_bib76","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for Acute Myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.coph.2025.102582_bib77","doi-asserted-by":"crossref","first-page":"12973","DOI":"10.1182\/blood-2022-165289","volume":"140","author":"Cooper","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102582_bib78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0145-2126(03)00180-2","article-title":"Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia","volume":"28","author":"Chang","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.coph.2025.102582_bib79","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","article-title":"CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?","volume":"9","author":"Maciocia","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.coph.2025.102582_bib80","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T cells for relapsed T-Cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102582_bib81","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1182\/blood-2022-168719","article-title":"Single and combinational multiplex base-edited \u201cUniversal\u201d CAR T cells in a humanised model of primary CD7+CD33+ AML","volume":"140","author":"Kloos","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102582_bib82","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018330","article-title":"Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden","author":"Biondi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102582_bib83","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1182\/blood-2021-153775","article-title":"Clinical-Scale production and characterization of Ntla-5001 - a novel approach to manufacturing CRISPR\/Cas9 engineered T cell therapies","volume":"138","author":"Cossette","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102582_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008174","article-title":"Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML","volume":"12","author":"Lo Presti","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coph.2025.102582_bib85","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia","volume":"381","author":"Xu","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:49:08Z","timestamp":1763758148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489225000785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":85,"alternative-id":["S1471489225000785"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2025.102582","relation":{},"ISSN":["1471-4892"],"issn-type":[{"type":"print","value":"1471-4892"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR-Cas9 in acute myeloid leukaemia: Current state-of-art and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2025.102582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102582"}}